Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kawasaki syndrome

A H Rowley1, S T Shulman

  • 1Loyola University Stritch School of Medicine, Maywood, Illinois 60153, USA. Arowley@wpo.it.luc.edu

Clinical Microbiology Reviews
|July 17, 1998
PubMed
Summary
This summary is machine-generated.

Kawasaki syndrome (KS) is a serious childhood vasculitis. Early treatment with IVGG and aspirin significantly reduces dangerous coronary artery abnormalities.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arterial immune protein expression demonstrates the complexity of immune responses in Kawasaki disease arteritis.

Clinical and experimental immunology·2017
Same author

CD84 is markedly up-regulated in Kawasaki disease arteriopathy.

Clinical and experimental immunology·2014
Same author

Human coronavirus-NL63 infection is not associated with acute Kawasaki disease.

Advances in experimental medicine and biology·2006
Same author

Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium.

Pediatric cardiology·2005
Same author

Recent developments and controversies in Kawasaki disease.

Minerva pediatrica·2004
Same author

Myocardial injury in children with respiratory syncytial virus infection.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2003
Same journal

Diagnostic challenges in re-emerging rickettsioses: why current tools fall short.

Clinical microbiology reviews·2026
Same journal

Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens.

Clinical microbiology reviews·2026
Same journal

The gut microbiome and colorectal cancer.

Clinical microbiology reviews·2026
Same journal

Influence of fungi on epithelial homeostasis and role in inflammatory diseases.

Clinical microbiology reviews·2026
Same journal

Coxsackievirus A6 on the rise: epidemiology, pathogenicity, evolutionary dynamics, and antiviral strategy.

Clinical microbiology reviews·2026
Same journal

Intravesical therapies for catheter-associated urinary tract infections: current approaches and future directions.

Clinical microbiology reviews·2026
See all related articles

Area of Science:

  • Pediatric Rheumatology
  • Cardiovascular Medicine
  • Infectious Disease Epidemiology

Background:

  • Kawasaki syndrome (KS) is an acute, potentially fatal vasculitis affecting young children.
  • KS is now the leading cause of acquired heart disease in US children, surpassing acute rheumatic fever.
  • The syndrome presents with fever, rash, and inflammation, but can lead to severe coronary artery abnormalities in 20% of untreated cases.

Purpose of the Study:

  • To summarize the clinical presentation, cardiovascular manifestations, and current treatment outcomes for Kawasaki syndrome.
  • To highlight the importance of early diagnosis and intervention in preventing long-term cardiac complications.
  • To emphasize the need for further research into the etiology of Kawasaki syndrome.

Main Methods:

Related Experiment Videos

  • Review of clinical and epidemiological features of Kawasaki syndrome.
  • Analysis of treatment efficacy for reducing coronary artery abnormalities.
  • Discussion of cardiovascular complications and their management.

    • Main Results:

    • Acute symptoms of KS are self-limiting, but coronary artery abnormalities develop in 20% of untreated children.
    • Treatment with intravenous gamma globulin (IVGG) and aspirin within 10 days of onset reduces coronary abnormalities from 20% to 4%.
    • Complications include myocarditis, pericardial effusion, and coronary artery aneurysms, potentially leading to myocardial infarction.

    Conclusions:

    • Early treatment of Kawasaki syndrome with IVGG and aspirin is crucial for preventing coronary artery abnormalities.
    • Understanding the unknown etiology of KS is vital for improved diagnosis, targeted therapies, and prevention strategies.
    • Ongoing research is necessary to address the challenges posed by this pediatric vasculitis.